The ideal approach depends on individual circumstances
The Phase 3 EGRIFTA trial data showing 15-18% VAT reduction at 26 weeks represents the strongest clinical evidence available for any peptide combination in this category
By alleviating oxidative stress, GPS effectively suppresses keratinocyte activation and subsequent inflammatory responses in the skin
It's important to note that individual responses to BPC-157 may vary, and factors like body weight, metabolism, and the severity of the condition can influence the appropriate dosage
As part of this trial, we acquired proton MR spectroscopy ( 1 H-MRS) data at pretreatment and ~ 8-weeks posttreatment in a subsample of ( n = 44) participants to evaluate whether NAC significantly affects frontal glutamate levels (i.e., represented by Glx, glutamate + glutamine), with exploratory evaluation of GABA and glutathione levels, and whether NAC-related changes in neurometabolite levels correspond to decreased drinking and/or PTSD symptoms, in people with PTSD + AUD
Ibuki N, Ghaffari M, Reuveni H, Pandey M, Fazli L, Azuma H, et al